Tanzania's oncology clinical trials market is projected to grow from $5.06 Mn in 2022 to $8.31 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. The market will be driven by the country's high cancer burden and its rising expenditure on research and development. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Roche Holding AG & Novartis International AG.
Tanzania's oncology clinical trials market is projected to grow from $5.06 Mn in 2022 to $8.31 Mn by 2030, registering a CAGR of 6.4% during the forecast period of 2022-30. Tanzania is home to the largest population in East Africa, with more than one-third of the population residing in the cities of Dar-es-Salaam, Mwanza, and Dodoma. Tanzania's high birth rate (35.3 births per 1,000 people), the high fertility rate (4.71 children per woman), and comparatively low life expectancy (61.6 years for males and 64.6 years for women) account for more than 60% of the population's age. As Tanzania moves closer to universal healthcare, the government has set aside $387.9 million for the health sector in 2020/2021, with $155.5 million going towards development projects to help the government execute its health-improving initiatives. Cancer is Tanzania's biggest non-communicable illness. Cervical cancer (25% of new cases in 2020), breast cancer (10%), and prostate cancer (9%). More than 26,000 people died from cancer in 2022.
Cancer is a major problem in the nation, with a high incidence of cervical, breast, and prostate cancer, among others. Because of the high occurrence of cancer, there is a chance to perform clinical trials and discover novel therapies. Efforts have been made in recent years to improve Tanzania's healthcare infrastructure and boost investment in research and development. To boost the country's research capacity, the government has developed research institutions and hospitals, as well as agreements with foreign organizations. The Tanzania Medicines and Medical Devices Authority (TMDA) and the Tanzania Commission for Science and Technology govern and supervise clinical research in Tanzania (COSTECH). Tanzania’s oncology clinical trials landscape is gradually evolving, with just a few clinical studies currently underway. Tanzania has a limited healthcare infrastructure, and the number of clinical trials done in the nation is low in comparison to other African countries.
Market Growth Drivers
One of the top reasons is the country's high cancer burden. Tanzania has high incidences of cervical, breast, and prostate cancer, among other cancers, which allows for clinical studies and the development of novel therapies. The country's rising expenditure on research and development boosts the country's research capacity, the government has developed research institutions and hospitals, as well as relationships with foreign organizations. Aga Khan Hospital Dar es Salaam, Bugando Medical Centre, Kilimanjaro Christian Medical Centre, and the Ocean Road Cancer Center are all major cancer treatment facilities. Also, foreign pharmaceutical firms are becoming interested in conducting clinical trials in Tanzania. This interest stems from the possibility of creating novel medicines and reaching a new patient group.
Despite a population of 54 million people, Tanzania has fewer than 5 radiation treatment devices in commercial and governmental institutions combined as of 2020. There are also barely around 20 oncologists operating in Tanzania. Tanzanians also have one of the world's lowest rates of access to health professionals. Over 60% of Tanzania's healthcare facilities are operated by the government, with the remaining being faith-based or private. Such a lack of proper infrastructure, human resources, and finance are some of the factors that might stifle the progress of oncology clinical trials in Tanzania. Another impediment is the absence of clinical trial regulatory and ethical standards. To guarantee that clinical trials are done in an ethical and safe way, specific rules and regulations must be established. Furthermore, Tanzania's political and economic instability may be a barrier to the expansion of oncology clinical trials. These variables may have an effect on the availability of money and investment, as well as the recruitment and retention of participants in clinical trials.
In December 2022, The Cancer Moonshot in a factsheet released additional steps to lower Africa’s cancer burden as part of the US - Africa leaders conference according to which:
The National Cancer Institute (NCI) has committed $48.5 Mn to assist HIV-Associated Malignancy Research Centers, which include several universities and scientists from the United States and throughout the African continent, including Tanzania.
With an initial financing commitment of more than $5 Mn, Global Health Catalyst will build a US-Africa Center of Excellence in Cancer Care, Research, and Teaching in Tanzania.
The American Childhood Cancer Organization offers financial assistance to identify hurdles to acquiring vital pediatric cancer treatments throughout East Africa, particularly Tanzania.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
188.8.131.52 Product Applications and Services
184.108.40.206 Recent Developments
220.127.116.11 Partnerships Ecosystem
18.104.22.168 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
6. Methodology and Scope
By Phase (Revenue, USD Billion):
By Study Design Outlook (Revenue, USD Billion):
By Indication Outlook (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses